SCOTTSDALE, AZ--(Marketwired - April 10, 2013) - Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.
Rafarma owns and operates a multi-profile pharmaceutical plant that is able to produce all types and forms of medical drugs in various pharmacological groups. The plant was constructed in the territory of a special industrial economic zone in Terbuny of the Lipetsk region of Russia. The project was initiated by the Zdorovie Foundation and is considered one of the grandest projects of the Russian medical industry in the last few years.
Michael McCarthy, Managing Director of QualityStocks, stated, "We have conducted extensive due diligence and are very excited to inform the investment community of Rafarma's corporate strategy and ongoing progress. Last month our team traveled over 6,000 miles to visit the company's 270,000 square-foot plant and take on-site video footage. We will be releasing a series of high-definition videos that fully encapsulate Rafarma's state-of-the art manufacturing facility and relay its legitimacy, opportunity, and enormity in the best way possible."
The first video produced by QualityStocks can be viewed at http://Video.QualityStocks.net.
QualityStocks has also put together a detailed, 10-page investor kit as well as a 34-slide presentation, both of which can be found at http://RAFA.QualityStocks.net.
Dave Anderson, CEO of Rafarma Pharmaceuticals, stated, "RAFA has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets."
About Rafarma Pharmaceuticals, Inc. (RAFA)
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net
Small Cap Stock Newsletter QualityStocks is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one free Daily Newsletter Report. QualityStocks also utilizes social media and networking to maintain constant communication with its rapidly growing audience. To date, QualityStocks has more than one million users following various social networking accounts.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
For more information, visit www.QualityStocks.net
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.